Ocuphire Pharma Results

Multiple Targets in DME/DR Treatment Landscape Anti-VEGF Therapy is Mainstay, but Under/Non-Responders Remain, and Early Treatment is Limited Available Commercialized Therapies: Anti-VEGF IVT: Aflibercept (Eylea®) Ranibizumab (Lucentis®) Bevacizumab (Avastin®) Faricimab (VabysmoⓇ) Emerging therapies that could shape industry: Longer Duration IVTs Oral Therapies Extended Release Topical Combination Therapies Gene Therapies Ocuphire PHARMA IVT Steroids: Dexamethasone (OzurdexⓇ) https://www.reviewofophthalmology.com/article/a-peek-into-the-diabetic-retinopathy-pipeline I aflibercept brolucizumab Port Delivery System with ranibizumab VEGF-R1 V VEGF-R2 100001 ☐☐OPT-302 GB-102 VEGF-R3 0008 Tyrosine kinase faricimab HA-1077 Rho-kinase KVD001 THR-149 THR-687 TIE2 Receptor RGX-314 ADVM-022 Integrin Receptor lasma kallikrein 000 7 Gene Therapy 25

View entire presentation